SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.
![Thumbnail](/bitstream/handle/internal/3024/%5b14796821%20-%20Endocrine-Related%20Cancer%5d%20SHH%20pathway%20inhibition%20is%20protumourigenic%20in%20adamantinomatous%20craniopharyngioma.pdf.jpg?sequence=76&isAllowed=y)
View/ Open
Date
2019-03-01Author
Carreno, G
Boult, JKR
Apps, J
Gonzalez-Meljem, JM
Haston, S
Guiho, R
Stache, C
Danielson, LS
Koers, A
Smith, LM
Virasami, A
Panousopoulos, L
Buchfelder, M
Jacques, TS
Chesler, L
Robinson, SP
Martinez-Barbera, JP
Type
Journal Article
Metadata
Show full item recordAbstract
Pharmacological inhibition of the sonic hedgehog (SHH) pathway can be beneficial against certain cancers but detrimental in others. Adamantinomatous craniopharyngioma (ACP) is a relevant pituitary tumour, affecting children and adults, that is associated with high morbidity and increased mortality in long-term follow-up. We have previously demonstrated overactivation of the SHH pathway in both human and mouse ACP. Here, we show that this activation is ligand dependent and induced by the expression of SHH protein in a small proportion of tumour cells. We investigate the functional relevance of SHH signalling in ACP through MRI-guided preclinical studies using an ACP mouse model. Treatment with vismodegib, a clinically approved SHH pathway inhibitor, results in a significant reduction in median survival due to premature development of highly proliferative and vascularised undifferentiated tumours. Reinforcing the mouse data, SHH pathway inhibition in human ACP leads to a significant increase in tumour cell proliferation both ex vivo, in explant cultures, and in vivo, in a patient-derived xenograft model. Together, our results demonstrate a protumourigenic effect of vismodegib-mediated SHH pathway inhibition in ACP.
Subject
Animals
Humans
Mice
Craniopharyngioma
Pituitary Neoplasms
Disease Models, Animal
Signal Transduction
Cell Proliferation
Adolescent
Child
Child, Preschool
Male
Hedgehog Proteins
Research team
Paediatric Solid Tumour Biology and Therapeutics
Pre-Clinical MRI
Language
eng
Date accepted
2019-01-15
License start date
2019-03
Citation
Endocrine-related cancer, 2019, 26 (3), pp. 355 - 366
Publisher
BIOSCIENTIFICA LTD